CIBC Asset Management
LYEL icon

CIBC Asset Management’s Lyell Immunopharma LYEL Stock Holding History

CIBC Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-526
Closed -$53K – 1388
2022
Q1 		$53K Hold
526
– – ﹤0.01% 1492
2021
Q4 		$81K Buy
+526
New +$117K ﹤0.01% 1497

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CIBC Asset Management's LYEL Position: Q2 2022 in Review

CIBC Asset Management sold out of Lyell Immunopharma (LYEL) in Q2 2022, closing a stake of 526 shares — an estimated $53K sold.

CIBC Asset Management first reported a position in LYEL in Q4 2021 and held it in 2 quarters. The position peaked at $81K in Q4 2021. 75 funds tracked by Wall St. Rank hold LYEL as of Q2 2022.

  • CIBC Asset Management reported no remaining Lyell Immunopharma position as of Q2 2022 after selling out during the quarter.
  • CIBC Asset Management sold 526 Lyell Immunopharma shares in Q2 2022, an estimated $53K.
  • CIBC Asset Management first reported a position in Lyell Immunopharma in Q4 2021 and held it in 2 quarters.
  • CIBC Asset Management's Lyell Immunopharma position peaked at $81K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.